Form 4: Teva Pharmaceutical Industries Director Tal Zvi Zaks Reports Transaction
SEC Form 4 Filing
Director Tal Zvi Zaks reports a transaction involving Teva Pharmaceutical Industries' ordinary shares and restricted share units.
Summary
- On June 15, 2024, Tal Zvi Zaks, a director of Teva Pharmaceutical Industries, reported a transaction.
- The transaction involved the acquisition of 21,108 ordinary shares through the vesting of restricted share units.
- Following the transaction, Zaks directly owns 49,140 ordinary shares.
- The restricted share units were granted on June 15, 2023, and vested on June 15, 2024.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted |
| 06/15/2024 | Date of transaction: Acquisition of ordinary shares through vesting of restricted share units; Restricted Share Units vested |
| 06/17/2024 | Date of report filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.